Gilead ax­es PhI­II tri­al for CD47 drug in lat­est set­back for $4.9B buy­out

Gilead will scrap one of three Phase III tri­als for ma­grolimab, the an­ti-CD47 drug at the heart of its $4.9 bil­lion ac­qui­si­tion of Forty Sev­en three years ago, while car­ry­ing on with the oth­er two.

In a late Fri­day state­ment, Gilead at­trib­uted the de­ci­sion to “fu­til­i­ty based on a planned analy­sis.” The tri­al be­ing stopped, EN­HANCE, was study­ing the use of ma­grolimab plus a type of chemother­a­py called azac­i­ti­dine (Vi­daza) in pa­tients with high­er-risk myelodys­plas­tic syn­dromes, or MDS.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER